Merck is fighting what it calls an “unprecedented” move to add administrative injury claims to a proposed multidistrict litigation proceeding over its HPV vaccine.
More than 30 lawsuits allege that Gardasil, approved for girls by the U.S. Food and Drug Administration in 2006 to prevent HPV, or human papillomavirus, which causes cervical cancer, has caused autoimmune disorders and other injuries. Claims over Gardasil must first go through Vaccine Court, after which plaintiffs who are either denied judgment or dissatisfied with the amount can bring lawsuits in U.S. courts.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
